Paksoy has advised Turkish biotechnology company Anatolia Geneworks on its TRY 516,9 million initial public offering.
The shares were admitted to trading on Borsa Istanbul on October 21, 2021. According to Anatolia, "the offering was oversubscribed 9.75-times with demand from 113,032 investors for shares with a total nominal value of TRY 20 million. In the offering made through a combination of capital increase and shareholder sales, 20.9% of Anatolia Geneworks shares were sold."
Anatolia is a molecular diagnostics company with expertise in designing, developing, and manufacturing Real-Time PCR kits, nucleic acid extraction kits, and automated nucleic acid extraction instruments.
"As one of the pioneers in the field of molecular diagnostics in Turkey, our biggest goal is to expand our product range, which is accepted worldwide, and to increase our market share and become one of the ten largest diagnostic companies in the world in the next 20 years," Anatolia Geneworks Chairman Alper Akyuz commented. "Achieving this success is our most significant debt to both our country and our investors."
Paksoy’s team included Partners Omer Collak and Sera Somay, Counsel Okkes Sahan, Senior Associates Soner Dagli and Merve Kurdak, and Associate Bulent Ozturk.
